GeneDx Holdings earnings release, August 3, 2026

GeneDx Holdings Corp. (WGS) · Form 8-K, Item 2.02 · Filed · SEC filing

GeneDx Reports Second Quarter 2026 Financial Results

• Reported second quarter 2026 revenue of $114.4 million, including $100.3 million in exome and genome revenue

• Reported exome and genome volume growth of 32% year-over-year

• Reported adjusted gross margin

Financial statements

Income Statement

Volume & Revenue

2Q261Q264Q253Q252Q25
VolumesWhole exome, whole genome30,78527,48827,76125,70223,246
VolumesOther panels32,05727,72931,28134,51434,510
VolumesTotal62,84255,21759,04260,21657,756
Revenue ($ millions)Whole exome, whole genome100.390.610498.986
Revenue ($ millions)Other panels11.610.713.314.614.1
Revenue ($ millions)Data information2.30.82.61.52
Revenue ($ millions)Software and interpretation services0.20.21.11.70.6
Revenue ($ millions)Total114.4102.3121116.7102.7

Income Statement

Three months ended June 30, 2026 — Unaudited Select Financial Information

Three months ended June 30, 2026 – ReportedThree months ended June 30, 2026 – Depreciation and amortizationThree months ended June 30, 2026 – Stock-based compensationThree months ended June 30, 2026 – Restructuring costsThree months ended June 30, 2026 – Change in FV of financial liabilitiesThree months ended June 30, 2026 – Other(2)Adjusted
Diagnostic test revenue111,886111,886
Other revenue2,5542,554
Total revenue114,440114,440
Cost of services36,202-1,726-561-4733,868
Gross profit78,2381,7265614780,572
Gross margin68.470.4
Research and development19,656-271-1,387-1,03616,962
Selling, general and administrative76,037-4,717-4,394-2,212-1,35363,361
(Loss) income from operations-17,4556,7146,3423,2951,353249
Interest expense, net-1,1851,185
Other income (expense), net382-220162
Income tax benefit518-518
Net (loss) income-17,7406,7146,3423,295-2202,020411
Basic (loss) earnings per share(1)-0.60.01
Diluted (loss) earnings per share(1)-0.60.01

Income Statement

Three months ended June 30, 2025 — Unaudited Select Financial Information

Three months ended June 30, 2025 – ReportedThree months ended June 30, 2025 – Depreciation and amortizationThree months ended June 30, 2025 – Stock-based compensationThree months ended June 30, 2025 – Restructuring costsThree months ended June 30, 2025 – Change in FV of financial liabilitiesThree months ended June 30, 2025 – Other(2)Adjusted
Diagnostic test revenue100,100100,100
Other revenue2,5922,592
Total revenue102,692102,692
Cost of services31,790-1,389-19330,208
Gross profit70,9021,38919372,484
Gross margin6970.6
Research and development15,079-209-1,42213,448
Selling, general and administrative46,863-4,593-6,198-736,93742,936
Income from operations8,9606,1917,81373-6,93716,100
Interest expense, net-817817
Other income (expense), net2,420-2,18149288
Income tax benefit246-246
Net income10,8096,1917,81373-2,181-6,31716,388
Basic earnings per share(1)0.380.57
Diluted earnings per share(1)0.360.55

Income Statement

Three months ended March 31, 2026 — Unaudited Select Financial Information

Three months ended March 31, 2026 – ReportedThree months ended March 31, 2026 – Depreciation and amortizationThree months ended March 31, 2026 – Stock-based compensationThree months ended March 31, 2026 – Restructuring costsThree months ended March 31, 2026 – Change in FV of financial liabilitiesThree months ended March 31, 2026 – Extinguishment of debtThree months ended March 31, 2026 – Other(2)Three months ended March 31, 2026 – Adjusted
Diagnostic test revenue101,299101,299
Other revenue955955
Total revenue102,254102,254
Cost of services34,043-1,462-38032,201
Gross profit68,2111,46238070,053
Gross margin66.768.5
Research and development19,804-224-1,406-22417,950
Selling, general and administrative74,591-5,123-7,210-215-1,91660,127
Impairment loss31,287-31,287
Loss from operations-57,4716,8098,99643933,203-8,024
Interest expense, net-717717
Other (expense) income, net-4,231-2,5406,565-206
Income tax expense-897897
Net loss-63,3166,8098,996439-2,5406,56534,817-8,230
Basic and diluted loss per share(1)-2.16-0.28

Income Statement

Three months ended June 30, — (in thousands, except share and per share amounts)

Three months ended June 30, – 2026Three months ended June 30, – 2025Six months ended June 30, – 2026Six months ended June 30, – 2025
RevenueDiagnostic test revenue111,886100,100213,185185,859
RevenueOther revenue2,5542,5923,5093,948
RevenueTotal revenue114,440102,692216,694189,807
RevenueCost of services36,20231,79070,24560,429
RevenueGross profit78,23870,902146,449129,378
RevenueResearch and development19,65615,07939,46027,656
RevenueSelling, general and administrative76,03746,863150,62897,313
RevenueImpairment loss31,287
Revenue(Loss) income from operations-17,4558,960-74,9264,409
Non-operating (expense) income, netChange in fair value of financial liabilities2202,1812,7601,081
Non-operating (expense) income, netInterest expense, net-1,185-817-1,902-1,457

Balance Sheet

December 31, 2025 — (in thousands, except share and per share amounts)

June 30, 2026 (Unaudited)December 31, 2025
Current assets:Cash and cash equivalents60,317104,997
Current assets:Marketable securities72,23166,285
Current assets:Accounts receivable83,61074,370
Current assets:Inventory, net17,82013,951
Current assets:Prepaid expenses and other current assets12,3828,685
Current assets:Total current assets246,360268,288
Current assets:Operating lease right-of-use assets33,53523,412
Current assets:Property and equipment, net54,31645,693
Current assets:Goodwill1,64113,520
Current assets:Intangible assets, net141,350168,481
Current assets:Other assets(1)4,2844,316
Current assets:Total assets481,486523,710
Current liabilities:Accounts payable and accrued expenses42,09157,645
Current liabilities:Short-term lease liabilities5,7094,404
Current liabilities:Other current liabilities26,82846,859
Current liabilities:Total current liabilities74,628108,908
Current liabilities:Long-term debt, net of current portion96,83648,176
Current liabilities:Long-term lease liabilities64,85756,046
Current liabilities:Other liabilities711,641
Current liabilities:Deferred taxes873757
Current liabilities:Total liabilities237,265215,528
Stockholders’ Equity:Class A common stock33
Stockholders’ Equity:Additional paid-in capital1,698,4271,680,738
Stockholders’ Equity:Accumulated deficit-1,454,551-1,373,495
Stockholders’ Equity:Accumulated other comprehensive income342936
Stockholders’ Equity:Total stockholders’ equity244,221308,182
Stockholders’ Equity:Total liabilities and stockholders’ equity481,486523,710

Cash Flow

Six months ended June 30, — (in thousands)

Six months ended June 30, – 2026Six months ended June 30, – 2025
Operating activitiesNet (loss) income-81,0564,280
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:Depreciation and amortization expense13,52311,869
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:Stock-based compensation expense15,33811,796
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:Change in fair value of financial liabilities-2,760-1,081
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:Deferred tax expense379202
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:Change in third party payor reserves-1,0225,014
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:Loss on extinguishment of debt6,565
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:Impairment loss31,287
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:Other2,1571,510
Change in operating assets and liabilities:Accounts receivable-9,240-9,889
Change in operating assets and liabilities:Inventory-3,973-1,404
Change in operating assets and liabilities:Accounts payable and accrued expenses-12,5667,199
Change in operating assets and liabilities:Other assets and liabilities-20,021-8,894
Change in operating assets and liabilities:Net cash (used in) provided by operating activities-61,38920,602
Investing activitiesAcquisition of business, net of cash acquired-33,195
Investing activitiesPurchases of marketable securities-29,065-30,770
Investing activitiesProceeds from sales of marketable securities2,272
Investing activitiesProceeds from maturities of marketable securities20,47526,705
Investing activitiesPurchases of property and equipment and development of internal-use software-16,567-8,498
Investing activitiesNet cash used in investing activities-22,885-45,758
Financing activitiesProceeds from long term debt, net of issuance costs96,699
Financing activitiesProceeds from offerings, net of issuance costs13,766
Financing activitiesProceeds from issuance of common stock from subscription agreements476
Financing activitiesProceeds from issuance of common stock pursuant to employee stock purchase plan1,7931,262
Financing activitiesExercise of stock options58800
Financing activitiesRepayment of long-term debt, including prepayment penalty - Perceptive-54,000
Financing activitiesRepayment and principal payments for long-term debt - DECD-4,447-602
Full release

(1) of 70% and adjusted net income

(1) of $0.4 million

• Reiterating full year 2026 revenue guidance of $475 to $490 million with exome and genome volume growth of at least 30%

• Hosting conference call today at 4:30 p.m. ET

GAITHERSBURG, Md., August 3, 2026 — GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the second quarter of 2026.

“Our team’s unwavering focus and agility drove a strong second quarter. By delivering healthy revenue, volume, and gross margin growth, we successfully navigated our return to profitability” said Katherine Stueland, CEO of GeneDx. “We are managing the transition to genome testing, making progress on each of our key imperatives — optimizing unit economics, growing utilization, and delivering the best products at unmatched scale — while continuing to extend our industry-leading position in both exome and genome testing to reach as many patients and families as soon as possible.”

Second Quarter 2026 Financial Results (Unaudited)

(1)

Revenue

• Revenue grew to $114.4 million, an increase of 11% year-over-year.

• Exome and genome test revenue grew to $100.3 million, an increase of 17% year-over-year.

Exome and genome volume

• Exome and genome test result volume grew to 30,785, an increase of 32% year-over-year.

Gross margin

• Adjusted gross margin of 70% in the second quarter of 2026 is up from 69% in the first quarter of 2026 and compares to 71% in the second quarter of 2025.

◦ GAAP gross margin was 68%.

Operating expenses

• Adjusted total operating expenses were $80.3 million, representing 70% of revenue.

◦ Total GAAP operating expenses were $95.7 million.

Net income

• Adjusted net income was $0.4 million, up $8.6 million from the first quarter of 2026 and compared to adjusted net income of $16.4 million in the second quarter of 2025.

◦ GAAP net loss was $17.7 million.

Cash position

• Cash, cash equivalents, marketable securities and restricted cash was $133.5 million as of June 30, 2026.

• On August 3, 2026, the Company amended and restated its existing loan agreement with Blackstone, adding an additional $50.0 million term loan facility and increasing the aggregate principal amount available under the facility to $150.0 million. Concurrently, an affiliate of Blackstone agreed to purchase approximately $5.0 million of the Company’s Class A common stock at $61.00 per share in a private placement.

◦ Combined with the cash, cash equivalents, marketable securities and restricted cash balance of $133.5 million as of June 30, 2026, the Company’s pro forma cash position following this transaction is approximately $188 million.

(1)

Adjusted gross margin, adjusted total operating expenses and adjusted net income are non-GAAP financial measures. See appendix for a reconciliation of GAAP to non-GAAP figures presented.

GeneDx 2026 Guidance

GeneDx has reaffirmed its full year 2026 guidance and has provided guidance for the third quarter of 2026. Management expects GeneDx to deliver:

Second Quarter 2026 and Recent Business Highlights

Strategic Expansion and Market Leadership

• Appointed Mark Gardner as President to lead GeneDx’s commercial and operations teams through the next phase of growth, with a focus on strengthening execution, scaling efficiently, and expanding the company’s leadership in genomic medicine.

• Launched redesigned exome and genome reports to streamline the delivery of genomic insights to non-genetics clinicians as part of a broader suite of customer experience improvements rolling out this summer.

Expanded Coverage for Exome and Genome

• Improved access to exome sequencing in Texas with new Medicaid coverage effective May 1, 2026, building on existing genome sequencing coverage in the state.

• Received California Medicaid (Medi-Cal) pricing for genome sequencing effective July 1, 2026, with pricing published at 100% of the Medicare rate. Coverage for genome sequencing in California was originally announced as effective November 1, 2025.

• Secured outpatient genome sequencing coverage from Carelon, the nation’s largest lab benefit manager, opening access to up to 56 million covered lives. The policy is effective June 14, 2026.

• Expanded the total number of state Medicaid programs covering outpatient exome and/or genome sequencing to 39 following Mississippi Medicaid’s announcement of coverage for both tests effective July 1, 2026.

Innovation and Clinical Leadership

• Contributed to 26 peer-reviewed publications, 41 conference presentations, and 50 abstracts in the first half of 2026, reflecting the depth and breadth of the Company’s scientific expertise and its commitment to moving the field forward.

Webcast and Conference Call Details

GeneDx will host a conference call today, August 3, 2026, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived webcast of the event will be available on the “Events” section of the GeneDx investor relations website at https://ir.genedx.com/.

Non-GAAP Financial Measures... (truncated)uld not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Reconciliations of non-GAAP financial measures to the most directly comparable financial results as determined in accordance with GAAP are included at the end of this press release following the accompanying financial data. We define non-GAAP financial measures as GAAP measures, excluding certain items such as stock-based compensation expense, depreciation and amortization, restructuring costs, changes in the fair value of financial liabilities, non-core lease costs, and other expenses that the Company believes are not indicative of its ongoing operations. A reconciliation of non-GAAP guidance measures to corresponding GAAP measures is not available on a forward-looking basis without unreasonable effort due to the uncertainty of expenses that may be incurred in the future. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding our future performance and our market opportunity, including our expectations for full year and third quarter 2026 revenue, exome and genome revenue and test volumes, adjusted gross margin and adjusted net income. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) our ability to implement business plans, goals and forecasts, and identify and realize additional opportunities, (ii) the risk of downturns and a changing regulatory landscape in the highly competitive healthcare industry, (iii) the size and growth of the market in which we operate, and

(iv) future expansion of insurance coverage for exome and genome testing. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on February 23, 2026, our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, filed with the SEC on May 4, 2026, our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, filed with the SEC on August 3, 2026, and other documents filed by us from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and we assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. We do not give any assurance that we will achieve our expectations.

About GeneDx

GeneDx’s (Nasdaq: WGS) mission is to empower everyone to live their healthiest life through genomics. GeneDx combines unmatched clinical expertise, advanced technology, and the power of GeneDx Infinity™ – the world’s largest rare disease genomic dataset. This unparalleled foundation powers GeneDx’s ExomeDx™ and GenomeDx™ tests – ranked #1 by expert geneticists and granted FDA Breakthrough Device designation – enabling clinicians to deliver precise, fast, and actionable diagnoses. GeneDx Infinity also fuels discovery for biopharma, with the most powerful AI-driven genomic intelligence. A genomics pioneer over the last 25 years, diagnosing more than 4,800 genetic diseases and publishing more than 1,100 research publications, GeneDx is building the network that will drive the future of genomic precision medicine. For more information, visit genedx.com and connect with us on LinkedIn, Facebook, and Instagram.

Investor Relations Contact:

Investors@GeneDx.com

Media Contact:

Press@GeneDx.com

Volume & Revenue

Unaudited Select Financial Information

(1)

Basic and diluted reported loss per share and Basic adjusted earnings per share are calculated based on 29,710,139 weighted average shares outstanding and Diluted adjusted earnings per share are calculated based on 30,144,132 weighted average shares outstanding for the three months ended June 30, 2026. Basic and diluted earnings per share are calculated based on 28,579,704 and 29,753,933 weighted average shares outstanding for the three months ended June 30, 2025, respectively.

(2)

Other represents interest expense, net, income tax benefit and non-core lease costs for all periods presented. For the three months ended June 30, 2026, Other also includes costs related to legal reserves. For the three months ended June 30, 2025, Other includes transaction costs incurred in connection with the acquisition of Fabric Genomics and a sales-and-use tax refund.

Unaudited Select Financial Information

(1)... (truncated)ch 31, 2026.

(2)

For the three months ended March 31, 2026, Other represents interest expense, net, income tax expense and non-core lease costs, costs related to legal reserves, and impairment of goodwill and intangible assets associated with the Fabric Genomics acquisition.

GeneDx Holdings Corp.

Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)

(1)

Other assets includes $1.0 million of restricted cash as of both June 30, 2026 and December 31, 2025.

GeneDx Holdings Corp.

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share amounts)

GeneDx Holdings Corp.

Condensed Consolidated Statements of Cash Flows (Unaudited)

(in thousands)

(1)

Cash, cash equivalents and restricted cash as of June 30, 2026 excludes marketable securities of $72.2 million.

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · GeneDx Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.